Insider Selling: Tandem Diabetes Care Inc (NASDAQ:TNDM) CFO Sells $950,400.00 in Stock

Tandem Diabetes Care Inc (NASDAQ:TNDM) CFO Leigh Vosseller sold 10,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $95.04, for a total transaction of $950,400.00. Following the completion of the sale, the chief financial officer now owns 14,520 shares of the company’s stock, valued at $1,379,980.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Leigh Vosseller also recently made the following trade(s):

  • On Thursday, July 2nd, Leigh Vosseller sold 20,000 shares of Tandem Diabetes Care stock. The shares were sold at an average price of $97.74, for a total transaction of $1,954,800.00.
  • On Thursday, May 7th, Leigh Vosseller sold 10,000 shares of Tandem Diabetes Care stock. The shares were sold at an average price of $90.07, for a total transaction of $900,700.00.

NASDAQ TNDM opened at $98.58 on Monday. The firm has a market cap of $5.92 billion, a price-to-earnings ratio of -298.72 and a beta of 0.58. The company has a 50 day moving average of $85.06 and a 200-day moving average of $73.87. The company has a current ratio of 2.82, a quick ratio of 2.21 and a debt-to-equity ratio of 0.09. Tandem Diabetes Care Inc has a 1-year low of $43.69 and a 1-year high of $103.95.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.07). The firm had revenue of $97.90 million for the quarter, compared to analyst estimates of $84.49 million. Tandem Diabetes Care had a negative return on equity of 9.39% and a negative net margin of 4.22%. The business’s quarterly revenue was up 49.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.40) EPS. On average, analysts forecast that Tandem Diabetes Care Inc will post -0.49 earnings per share for the current year.

Institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its holdings in shares of Tandem Diabetes Care by 21.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 750,426 shares of the medical device company’s stock valued at $44,733,000 after purchasing an additional 134,544 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Tandem Diabetes Care in the first quarter valued at approximately $36,000. Invesco Ltd. boosted its stake in Tandem Diabetes Care by 110.6% in the first quarter. Invesco Ltd. now owns 1,663,692 shares of the medical device company’s stock valued at $107,059,000 after acquiring an additional 873,780 shares during the last quarter. Great West Life Assurance Co. Can bought a new position in Tandem Diabetes Care in the fourth quarter valued at approximately $209,000. Finally, Guggenheim Capital LLC boosted its stake in Tandem Diabetes Care by 22.9% in the fourth quarter. Guggenheim Capital LLC now owns 4,577 shares of the medical device company’s stock valued at $273,000 after acquiring an additional 854 shares during the last quarter. 93.44% of the stock is owned by institutional investors and hedge funds.

A number of research firms have issued reports on TNDM. SVB Leerink upped their price target on shares of Tandem Diabetes Care from $85.00 to $88.00 and gave the company a “market perform” rating in a report on Friday, May 1st. Craig Hallum decreased their price target on shares of Tandem Diabetes Care from $108.00 to $102.00 and set a “buy” rating for the company in a report on Monday, April 20th. UBS Group increased their target price on shares of Tandem Diabetes Care from $98.00 to $106.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. BidaskClub cut shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Thursday, May 28th. Finally, Stifel Nicolaus increased their target price on shares of Tandem Diabetes Care from $65.00 to $75.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $93.31.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Read More: What is the Quick Ratio?

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.